Renovia receives FDA clearance for leva® Pelvic Health System as first-line treatment for chronic fecal incontinence
Clearance for new indication follows FDA Breakthrough Device Designation
BOSTON, July 7, 2022 /PRNewswire/ — Renovia Inc. (“Renovia”), a developer of non-surgical, treatments for female pelvic floor disorders and an advocate for women’s health, announced today that the U.S. Food and Drug Administration (FDA) has cleared its leva® Pelvic Health System for the first-line treatment of chronic fecal incontinence (FI) in women. The decision follows the grant of Breakthrough Device Designation by FDA in October 2021. leva had previously been cleared by FDA to treat stress, mixed and mild-to-moderate urinary incontinence (UI) in women. The new indication makes first-line, at-home treatment for FI, also called accidental bowel leakage, available to the over 12 million U.S. women who suffer from the debilitating and progressive condition.
FI, typically defined as the uncontrolled passage of feces, is associated with greater risk of depression, social isolation and nursing home placement. Traditional first-line treatment is limited and includes dietary changes, over-the-counter antidiarrheal medications and rectal biofeedback devices. These treatments are challenging, and there is a need for additional options.
The leva System is designed to treat FI through helping women strengthen their pelvic floor muscles, including the puborectalis muscle, the muscle that acts as a sling around the rectum and the vagina and contributes directly to fecal continence. leva is a prescription digital therapeutic (PDT) that guides a woman through pelvic floor muscle training (PFMT). Combining a small vaginal motion sensor with a smartphone app, leva offers an easy, non-invasive, drug-free way for women to perform PFMT to improve FI symptoms. leva requires just five minutes of training a day, which women can do at home, on their own schedule.
“I’ve spent over 20 years studying the causes and treatments for fecal incontinence,” said Holly E. Richter, PhD, MD, Professor and The Endowed Chair in Obstetrics and Gynecology at the University of Alabama at Birmingham, (UAB) and Associate Director, Gynecologic Research in the UAB Center for Women’s Reproductive Health. “First-line treatment alternatives have been limited in the past so it’s important that clinicians can now consider leva as a new treatment option that is supported by robust clinical data.”
“In my clinical practice, accidental bowel leakage is among the conditions that has the most negative effect on patients’ emotional well-being,” said Roger R. Dmochowski, MD, MMHC, Professor of Urology and Surgery and Associate Surgeon-in-Chief at Vanderbilt University Medical Center. “Fewer than 30% of women seek care for FI, suggesting the depth of embarrassment and shame patients experience. My hope is that better first-line treatment options, like leva, will lead more women to seek care. The ability of a single noninvasive therapy to treat both conditions is really very helpful to our patients. Now with FDA approval, patients will have much improved ability to use this efficacious therapy on a long-term basis, which is most beneficial for them.”
“We’re gratified that the FDA has cleared this new indication for the leva Pelvic Health System as we now have a tremendous opportunity to treat a condition that’s been cloaked in silence for too long.,” said Renovia’s CEO Eileen Maus. “leva’s popularity among women with urinary incontinence already made it a great choice for providers, particularly OB/GYNs, who are at the frontlines of women’s care. leva enables discreet, at-home, non-surgical, drug-free symptom relief, which we believe positions it to dramatically improve women’s access to improved first-line care.”
In November 2019, leva was FDA cleared for the treatment of stress, mixed and mild to moderate urgency urinary incontinence (including overactive bladder) in women. In April 2022, Obstetrics and Gynecology (The Green Journal), published a randomized controlled superiority study showing that leva was statistically and clinically superior to Kegel exercises alone for improving symptoms of stress and stress-dominant mixed urinary incontinence. Kegel exercises, a commonly used term for pelvic floor muscle exercises (PFMT), are performed in the practice of PFMT.
About the leva® Pelvic Health System
The leva Pelvic Health System offers a novel, non-invasive, medication-free way for women to train and strengthen their pelvic floor muscles—at home in just five minutes a day—to treat urinary incontinence (UI) and chronic fecal incontinence (FI). Combining a small FDA-cleared vaginal motion sensor connected to a smartphone app, leva offers precise visualization of pelvic movement in real-time, enables progress tracking and allows active clinician involvement, all of which support women’s success. Recognizing that level-one evidence shows pelvic floor muscle training is most effective when performed under the supervision of a skilled healthcare provider, leva is available by prescription only, allowing clinicians the opportunity to treat UI and chronic FI on a broad scale and with deep involvement in patient success. leva is the first femtech product included in the Digital Therapeutics Alliance product library and has multiple clinical trials and published data from globally recognized medical centers supporting its efficacy. leva received the 2021 Excellence Award for Research from Medical Device Network.
Boston-based Renovia Inc. is a women-led company dedicated to improving the lives of women with pelvic floor disorders. Renovia’s flagship product, the leva® Pelvic Health System, offers a novel, effective, first-line treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), underreported conditions affecting over 78 million and 12 million women in the U.S. Renovia’s technology enables non-invasive, drug-free treatment via precise visualization of movement in real time during pelvic floor muscle training, while monitoring usage and progress. For more information about Renovia or leva please visit www.renoviainc.com and www.levatherapy.com and follow us on Twitter, Facebook, LinkedIn and Instagram.
Important Indication and Other Information for the leva Pelvic Health System
The leva Pelvic Health System is intended for (1) strengthening of pelvic floor muscles, (2) rehabilitation and training of weak pelvic floor muscles for the treatment of stress, mixed, and mild to moderate urgency urinary incontinence (including overactive bladder) in women and (3) rehabilitation and training of weak pelvic floor muscles for the first-line treatment of chronic fecal incontinence (>3-month uncontrolled passage of feces) in women. Treatment with the leva System is by prescription and is not for everyone. Please talk to your prescriber to see if leva is right for you. Your prescriber should discuss all potential benefits and risks with you. Do not use leva while pregnant, or if you think you may be pregnant, unless authorized by your doctor. For a complete summary of the risks and instructions for the leva System, see its Instructions for Use available at www.renoviainc.com and www.levatherapy.com.
Renovia Inc. and leva® are trademarks or registered trademarks of Renovia Inc. in the United States and other countries. All Rights Reserved.
Media inquiries: Shanti Skiffington mobile: 617 921-0808